RANI — Rani Therapeutics Holdings Share News
0.000.00%
Last trade - 00:00- $15.20m
- -$29.44m
- $1.63m
Brief: Rani Therapeutics Unit And Celltrion Entered Into A License And Supply Agreement
Brief: Rani Therapeutics Appoints Kate Mckinley As Chief Business Officer
Brief: Rani Therapeutics Reports First Quarter 2023 Financial Results
Rani Therapeutics Holdings Inc reports results for the quarter ended in December - Earnings Summary
Brief: Rani Therapeutics Reports Fourth Quarter Financial Results
Rani Therapeutics Holdings Inc expected to post a loss of 35 cents a share - Earnings Preview
Brief: Rani Therapeutics Holdings Inc Says On January 6, Rani Therapeutics, Llc, Operating Unit Co And Celltrion, Inc. Entered Into License And Supply Agreement
Brief: Rani Therapeutics Receives Feedback From Pre-Ind Meeting With FDA Provides Pipeline Update
Brief: Rani Therapeutics Says Files Prospectus Relates To Resale From Time To Time Of Up To About 6 Million Shares Of Class A Common Stock By Selling Stockholders
Brief: Rani Therapeutics Announces Repeat-Dose Topline Results From RT-102 Phase 1 Study
Brief: Rani Therapeutics Holdings Inc Reports Quarterly Loss Per Share Of $0.33
Brief: Rani Therapeutics Announces New RT-111 Development Program
U.S. RESEARCH ROUNDUP- PLx pharma, Vroom, Walmart
Rani Therapeutics rebounds after co scraps stock offering
Brief: Rani Therapeutics Announces Termination Of Public Offering Of Class A Common Stock
Brief: Rani Therapeutics Reports Second Quarter 2022 Financial Results Provides Corporate Update
Brief: Rani Therapeutics Holdings Inc - Capitalized To Fund Operations Into Mid-2024
Brief: Rani Therapeutics Announces Positive Topline Results From Phase 1 Study Of Rt-102 In Osteoporosis
Brief: Rani Therapeutics Enters Into $45 Mln Loan Agreement To Support Ranipill Platform Advancement